Investor Resources

Addressing the Unmet Need for Novel Safe and Effective Therapies for Pain and Inflammation

Pain and inflammation represent a vast and prevalent problem, and current medications all have major limitations. There is an urgent need and opportunity for a better solution.

EicOsis Human Health aims to provide a new effective oral solution for pain and inflammation without the side effects of standard therapies and without addiction potential. We are a clinical stage company with a strong team advancing inhibitors of soluble epoxide hydrolase (sEHI) as a novel therapeutic approach. Our lead drug candidate EC5026 has completed a Phase 1a clinical study showing safety and an ideal pharmacokinetic profile as a once daily oral drug. Contact us for more information and to learn more about what’s going on at EicOsis.

A Ready Market for Better Pain Drugs

Pain drugs are one of the largest pharmaceutical markets, and yet current drugs fail to meet the needs of millions:

  • There are 4.5 million painful diabetic neuropathy patients and 16-21 million osteoarthritis patients in the US*
  • Despite its limitations, sales of Lyrica (pregabalin) were $3.6 Billion in the US alone in 2018.
  • Only a third of patients with painful diabetic neuropathy are treated for their pain*
  • The 2023 total global pain therapeutics market is estimated to be worth a staggering $85 billion*
*Arrowhead Global Pain Therapeutics Market, 6th Edition, 2019
Man sitting and reading the business section of a newspaper

EicOsis receives investments and grants to support advancing our lead candidate pain drug to the clinic

EicOsis is a privately held company developing a first-in-class therapy for neuropathic and inflammatory pain in humans and companion animals. The technology for the lead compounds was developed largely at the University of California, Davis by EicOsis CEO and UC Professor, Dr. Bruce Hammock, and licensed exclusively to EicOsis. EicOsis has received several competitive grants from the National Institutes of Health (NIH), including an NIH SBIR Blueprint Development Grant and a $15MM NIDA Grant to cover development costs through Phase 1b Clinical Trials. An additional $5MM in Venture Philanthropy was also raised.

EicOsis’s Innovative Approach has been Recognized by Prestigious Awards

EicOsis LLC was recently named “Innovator of the Year” in the Sacramento region. Read more